Two distinct experimental peptides with limited, non-interchangeable evidence.
Bottom line: No adequate head-to-head study shows that one is better, and no validated stack has been established. The often-cited Selank anxiety study compared it with medazepam, not placebo. Semax reports involve specific neurological populations. [1,3]
| Selank | Semax | |
|---|---|---|
| Human evidence | Small 62-person active-comparator anxiety study; no placebo and no detailed abstract effect sizes. [1] | Limited regional studies in neurologic populations; not proof of healthy-person cognitive enhancement. [3] |
| Approved use in the United States | None. [2] | None. [4] |
| Dose or stack | No validated routine consumer plan. | No validated routine plan or Selank/Semax combination. |
summary: No adequate head-to-head study shows that one is better, and no validated stack has been established. The often-cited Selank anxiety study compared it with medazepam, not placebo. Semax reports involve specific neurological populations. [1,3]
trials: []
No. It compares evidence and status. Use the exact approved label and prescriber plan, or a registered clinical-trial protocol if you are enrolled.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
